Back to Agenda
Session 2: PSUR Repository – Achievements and Next Steps
Session Chair(s)
David John Lewis, PHD
Former Head QPPV PRRC Office, Patient Safety & Pharmacovigilance, Novartis Pharma Gmbh, Switzerland
Irene Rager
Head of Service E, Procedure Management Department, European Medicines Agency, Netherlands
This session will focus on the latest PSUR Repository achievements and next steps towards the simplification of PSUR submissions benefiting pharmaceutical industry and NCAs taking into account that the Repository will be mandatory on 13 June 2016.
Speaker(s)
Steven J. Blumenthal, MSC
Director, Global Safety, Merck & Co., Inc., United States
Experience with the use of the Repository
Ana Zanoletty Perez
Head of Clinical Trials Transformation Workstream, European Medicines Agency, Netherlands
PSUR Repository – Status Update and Next Steps
David John Lewis, PHD
Former Head QPPV PRRC Office, Patient Safety & Pharmacovigilance, Novartis Pharma Gmbh, Switzerland
Panel Discussion
Have an account?